Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Gilead Sciences (GILD – Research Report), Rhythm Pharmaceuticals (RYTM – Research Report) and Dexcom (DXCM – Research Report).
Gilead Sciences (GILD)
In a report released yesterday, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences, with a price target of $74.00. The company’s shares closed last Thursday at $65.27, close to its 52-week low of $65.09.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
Currently, the analyst consensus on Gilead Sciences is a Moderate Buy with an average price target of $84.55, a 25.3% upside from current levels. In a report issued on April 15, Truist Financial also initiated coverage with a Hold rating on the stock with a $82.00 price target.
See the top stocks recommended by analysts >>
Rhythm Pharmaceuticals (RYTM)
In a report released today, Joseph Stringer from Needham maintained a Buy rating on Rhythm Pharmaceuticals, with a price target of $50.00. The company’s shares closed last Thursday at $38.15.
According to TipRanks.com, Stringer is a 2-star analyst with an average return of
Rhythm Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $56.29, a 45.2% upside from current levels. In a report issued on April 16, Bank of America Securities also maintained a Buy rating on the stock with a $49.00 price target.
Dexcom (DXCM)
In a report released yesterday, Shagun Singh Chadha from RBC Capital reiterated a Buy rating on Dexcom, with a price target of $165.00. The company’s shares closed last Thursday at $138.01, close to its 52-week high of $142.00.
According to TipRanks.com, Chadha is a 2-star analyst with an average return of
Dexcom has an analyst consensus of Strong Buy, with a price target consensus of $154.29, which is an 11.1% upside from current levels. In a report issued on April 10, UBS also maintained a Buy rating on the stock with a $163.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on GILD:
- Options Volatility and Implied Earnings Moves Today, April 25, 2024
- Gilead upgraded to Hold from Reduce at HSBC
- Gilead Sciences (GILD) Q1 Earnings Cheat Sheet
- Gilead price target lowered to $75 from $78 at Cantor Fitzgerald
- Options Volatility and Implied Earnings Moves This Week, April 22 – April 26, 2024
